Blood and serum components and organ weights in steers, bulls and zeranol-implanted bulls

Effects of increasing dosages of zeranol implants on lamb growth, carcass characteristics, blood hormones, and nitrogen metabolism

The objective of this research was to compare the growth performance, incidence of prolapse and mortality, carcass characteristics, blood hormone concentration, and N balance of lambs implanted with increasing dosages of zeranol. One hundred forty-four crossbred lambs (29.6 ± 4.9 kg) were used in a completely random design and placed into 16 feedlot pens (4 pens/treatment) for a 116 d finishing study. Lambs were fed an 84.7% corn and 15.3% market lamb pellet (DM basis) diet ad libitum. Treatments were 0, 12, 24, and 36 mg zeranol (Ralgro; Schering-Plough), and lambs were implanted in the ear according to treatment on d 0. Lambs were weighed. Thirty lambs (67.6 ± 3.4 kg) and 96 lambs (65.8 ± 5.1 kg) were harvested on d 84 and d 118, respectively. Carcass data were collected 24 h after chill. Blood samples were collected on d 0, 28, 56, 70, 82, 99, and 116 from 64 lambs (29.6 ± 2.1 kg) in the feedlot study (subsample of 4 lambs per pen) and analyzed for thyroxine, triiodothyronine, and IGF-I. A second study was conducted to compare effects of 0, 12, 24, or 36 mg zeranol on N balance in 16 crossbred lambs (34.8 ± 2.1 kg). There were no differences among treatments for BW, ADG, DMI, and G:F (P > 0.05) in the feedlot study. However, there was a linear increase for incidence of prolapse (P = 0.006; 2.78, 5.55, 24.98, and 27.75%, respectively) and mortality (P = 0.005; 0.00, 5.55, 11.10, and 13.88%, respectively) as zeranol dosage increased. Carcass characteristics, blood hormone concentrations, and N balance were not affected by treatment (P > 0.05). These results indicate zeranol increases incidence of prolapse and mortality without increasing growth performance.

Pharmacological and toxicological assessment of a potential GnRH vaccine in young-adult male pigs

Active immunization against gonadotrophin-releasing hormone (GnRH) is successfully applied to prevent boar taint in pork. In men, GnRH immunization could be an alternative to hormone therapy in patients with prostate cancer. In this study, a new GnRH vaccine formulation (a modified GnRH peptide conjugate formulated with CoVaccine adjuvant) was investigated for its pharmacological efficacy and safety in young-adult male pigs. Immunization resulted in castrate-like plasma testosterone levels in all treated pigs from week 8 until the end of the study, 30 weeks after the first immunization. Testosterone depletion retarded testes growth, reduced the relative weight of the testes and accessory sex organs, and reduced sperm counts and motility. There was no clinically relevant toxicity. Typical vaccination-related adverse reactions, such as swelling at the injection site and fever, were considered acceptable. We conclude that this GnRH vaccine efficiently and rapidly reduced serum testosterone levels, without inducing chronic toxic effects, and therefore could be applicable in both veterinary and human medicine.